Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash from Financing Activities (2024 - 2025)

Indivior Pharmaceuticals has reported Cash from Financing Activities over the past 2 years, most recently at -$5.0 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$5.0 million for Q4 2025, down 112.5% from a year ago — trailing twelve months through Dec 2025 was -$30.0 million (up 70.59% YoY), and the annual figure for FY2025 was -$30.0 million, up 70.59%.
  • Cash from Financing Activities for Q4 2025 was -$5.0 million at Indivior Pharmaceuticals, down from -$3.0 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for INDV hit a ceiling of $40.0 million in Q4 2024 and a floor of -$56.0 million in Q1 2024.